Moderna Therapeutics instates MIT Treasurer to Board of Directors
pharmafile | February 27, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | MIT, Moderna, Moderna Therapeutics
Moderna Therapeutics, a clinical stage biotechnology company, has announced the appointment of Israel Ruiz to the company’s Board of Directors. Israel Ruiz is currently the Executive Vice President and Treasurer at the Massachusetts Institute of Technology (MIT).
Ruiz has worked at MIT for many years, leading to his current role in 2011. The role puts him in charge of $17 billion of financial assets, $3.4 billion in operating revenues and makes him responsible for administering MIT’s $5 billion capital plan through to 2030. He also works as Audit Committee Chair on the Board of Directors of Fortive, an industrial growth company.
“At MIT, we are driven to bring knowledge to bear on the world’s great challenges, and I see this same spirit of intellect and impact embodied by the Moderna team. They are working with rigor and intensity to drive breakthroughs in both science and technology with the goal of delivering a new class of medicines to address significant medical challenges and unmet needs around the world,” said Mr. Ruiz. “I am extremely honoured to join Moderna’s Board, and look forward to lending my support to help further advance the mission and vision of this unique and immensely exciting company.”
“We are delighted to welcome Israel to Moderna’s Board of Directors. His progressive leadership at MIT has helped ensure the continued, unparalleled contributions of the Institute on a regional, national and global scale, through education, innovation and entrepreneurship,” said Noubar Afeyan, co-founder and Chairman, Moderna Therapeutics, and CEO of Flagship Pioneering. “We look forward to leveraging Israel’s insights as Moderna evolves into a leading, clinical stage biotechnology company by harnessing the promise of messenger RNA science to improve lives.”
Related Content
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase …
Moderna expands use of AI-ready R&D platform
Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader …
Moderna authorised to upscale development of mRNA vaccines in UK
Global researcher of mRNA medicine, Moderna, has been granted authorisation by the Medicines and Healthcare …
